Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Mellaril Shifted To Second-Line Anti-Psychotic With QTc Black Box

Executive Summary

Novartis Mellaril's black box warning that thioridazine causes QTc prolongation will shift it to a second-line anti-psychotic therapy.

You may also be interested in...



Pfizer Ziprasidone Labeling Stops Short Of Second-Line Use; QT Effect Noted

Labeling for Pfizer's ziprasidone (Zeldox) recommends that doctors first consider prescribing antipsychotic agents associated with lower rates of QTc prolongation, but stops short of a second-line designation for the drug.

Pfizer Ziprasidone Labeling Stops Short Of Second-Line Use; QT Effect Noted

Labeling for Pfizer's ziprasidone (Zeldox) recommends that doctors first consider prescribing antipsychotic agents associated with lower rates of QTc prolongation, but stops short of a second-line designation for the drug.

Novartis/Boehringer-Ingelheim Serentil

Boxed warning about potential QTc prolongation associated with antipsychotic mesoridazine is added to labeling, and product is restricted to second-line status. The change is similar to a July relabeling for Novartis' chemically-related product Mellaril (1"The Pink Sheet" July 17, p. 12). Mesoridazine is a Mellaril (thioridazine) metabolite

Related Content

UsernamePublicRestriction

Register

PS036351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel